



Monday 18 May 10.05 - 11.05 Ocular toxicities secondary to systemic therapeutic agentserapeutic agents

The occurrence of ocular toxicities secondary to use of medications for systemic conditions is raising, especially following the development of immunotherapies for cancer, and targeted therapies. As ophthalmologists, we need to be vigilant on these events. Timely recognition, discussion with physicians and decision on medication cessation or potential treatment, where available, are paramount. During the course, the speakers will outline the most common ocular toxicity features from use of systemic medications such as hydroxychloroquine, tamoxifen, pentosan polysulfate sodium (PPS), MEK inhibitors, checkpoint inhibitors, ALK inhibitors, EGFR inhibitors and FGFR inhibitors. The course will review retinal and corneal toxicities. Case-studies will be presented. There will be a focus on recognition of these events. The best way to set up an effective collaboration between Ophthalmology and Oncology Units will also be discussed, including challenges and implications for Ophthalmology Units due to increased capacity needs. The course will also include a lecture from an oncologist to outline the physicians' general point of view of the area.

10.05 – 10.07 Introduction

Miss Simona Degli Esposti & Prof Tariq Aslam

10.07 – 10.17 Commonly used systemic medications causing retinal toxicity (including hydroxychloroquine, tamoxifen and pentosan polysulfate sodium)

Miss Simona Degli Esposti, consultant ophthalmologist, London

10.17 – 10.27 The anticancer revolution and its impact on ophthalmology

Prof Tariq Aslam, consultant ophthalmologist, Manchester

10.27 – 10.37 Drug-induced corneal toxicity from new oncology agents

Mr Daniel Sibley, consultant ophthalmologist, London

10.37 – 10.47 New anticancer drugs, and potential implications for patients and ophthalmologists. The oncologist's point of view

Dr Donna Graham, consultant oncologist, Manchester

10.47 – 10.57 How to set up a monitoring system. Challenges and potential solution

Panel, discussion facilitated by chairs

10.57 – 11.05 Discussion and Q&A – Panel